We
are developing a more effective, longer-lasting, and precisely tunable therapy to manage neuropathic pain.
820 million people are impact by neuropathic pain globally, accounting for billions of dollars in healthcare costs. Current treatment options only address symptoms of pain, not the
root cause. That's where we come in.
Our Solution
We are developing a DNA plasmid-based drug therapy as a novel, effective, reversible, and long-lasting therapeutic strategy against neuropathic pain.
Our Target
Nav1.7 is a well-established target to treat pain as it has been shown to play a critical role in the modulation of pain signals, adding credence to our scientific approach.
Our Market
The global management pain market is expected to reach $110B by 2033. Over the same time period, the market for neuropathic pain is expected to eclipse $13B,
Our Advantage
Our technology will not require specialized facilities or equipment for manufacturing and anticipate significantly lower costs than other current gene therapy technologies.
